U.S. Markets open in 1 hr 31 mins

Regulus Therapeutics Inc. (RGLS)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.12-0.07 (-5.88%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close1.19
Bid0.95 x 2000
Ask1.39 x 200
Day's Range1.08 - 1.21
52 Week Range0.86 - 3.92
Avg. Volume874,257
Market Cap116.24M
PE Ratio (TTM)-0.73
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com2 days ago

    Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares

    President and CEO of Regulus Therapeutics Inc (NASDAQ:RGLS) Joseph P Hagan bought 219,780 shares of RGLS on 07/25/2017 at an average price of $0.91 a share.

  • SmarterAnalystlast month

    Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations

    Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced three program discontinuations, which include drugs: RG-101, a miR-122 inhibitor for the treatment of hepatitis C, RG-125, a miR-103/107 inhibitor for the treatment of non-alcoholic steatohepatitis, and RGLS5040, a miR-27 inhibitor for the treatment for cholestatic disorders. In the wake of the clinical updates, Chardan analyst Madhu Kumar slashed his price target to $5.00 (from $2.50), while reiterating a Buy rating on the stock. To the company’s credit, the analyst points out that the company's lead drug RG-012, a miR-21 inhibitor for the treatment of Alport syndrome, is still on the run and has a “favorable risk-benefit profile." Kumar reminds “The phase II HERA trial is expected to provide renal biopsy data by year end-2017 and interim efficacy data by mid-2018,” and highlights the drug maker’s future is strongly linked to RG-012 performance.

  • TheStreet.comlast month

    Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

    After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.